General Information


We are a biopharmaceutical company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Our proprietary, first-of-its kind platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, which we refer to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by our new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. Our lead product candidate, THOR-707, is a variant of IL-2 designed to kill tumor cells by increasing CD8+ T and natural killer, or NK, cells without causing vascular leak syndrome, or VLS, observed with approved recombinant IL-2 (aldesleukin).

Employees: 25
Founded: 2014
Contact Information
Address 11099 N. Torrey Pines Road, Suite 290, La Jolla, CA 92037, US
Phone Number (858) 750-4700
Web Address
View Prospectus: Synthorx
Financial Information
Market Cap $332.5mil
Revenues $0 mil (last 12 months)
Net Income $-30.6 mil (last 12 months)
IPO Profile
Symbol THOR
Exchange NASDAQ
Shares (millions): 11.9
Price range $11.00 - $11.00
Est. $ Volume $131.0 mil
Manager / Joint Managers Jefferies/ Leerink Partners/ Evercore ISI
CO-Managers H.C. Wainwright & Co.
Expected To Trade: 12/7/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change